Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Colorectal Neoplasms 882Pancreatic Neoplasms 573Carcinoma, Hepatocellular 543Stomach Neoplasms 513Esophageal Neoplasms 312Rectal Neoplasms 282Colonic Neoplasms 255Breast Neoplasms 204Neoplasms 201Liver Neoplasms 187Lung Neoplasms 175Carcinoma, Non-Small-Cell Lung 175Cholangiocarcinoma 152Ovarian Neoplasms 142Neoplasm Metastasis 137Gastrointestinal Neoplasms 134Esophageal Squamous Cell Carcinoma 130Melanoma 103Prostatic Neoplasms 99Biliary Tract Neoplasms 95Endometrial Neoplasms 83Uterine Cervical Neoplasms 79Head and Neck Neoplasms 72Squamous Cell Carcinoma of Head and Neck 69Carcinoma, Renal Cell 58Sarcoma 55Adenocarcinoma Of Esophagus 54Urinary Bladder Neoplasms 53Anus Neoplasms 52Triple Negative Breast Neoplasms 48

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lethal Congenital Contracture Syndrome 2 × Gastrointestinal × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡